Sam Brusco, Associate Editor06.16.22
Biomarker-guided digital therapeutics company Bodyport has appointed medtech industry veteran John Lipman as its new CEO. Bodyport co-founder Cory Centen will continue as the company’s president and also serve as chief technology officer.
Bodyport is preparing to commercialize its Bodyport Cardiac Scale, which remotely and noninvasively analyzes heart function and fluid status in people with fluid management conditions.
“I joined Bodyport to help make a difference in patients’ lives. I truly believe our simple, intuitive biomarker platform will be able to do just that,” Lipman told the press. “Bodyport’s growing clinical evidence and commitment to a robust clinical roadmap have the potential to help detect heart failure events accurately and catch them earlier from the comfort of the patient’s home. I look forward to working together with our incredibly talented team and am eager to bring our solutions to market.”
Lipman has over 25 years of leadership experience in the medical device industry. He was most recently president of North America for Qualta Dialysis Technologies. Before that, he was chief commercial officer at NightBalance prior to its acquisition by Philips. He was also previously VP of marketing and sales at ApniCure, and held positions at two Johnson & Johnson subsidiaries, LifeScan and Scios.
“I am delighted to welcome John to the team during this important phase of our growth,” Centen said. “In my new role as president and CTO, I am excited to lead the development of our novel biomarker pipeline and prediction algorithms for managing cardiorenal conditions.”
“John’s extensive industry experience will prove to be a valuable resource to the Bodyport team,” said Phyllis Whiteley, Ph.D., Chair of Bodyport’s board of directors. “We are excited to welcome John as Bodyport’s CEO and look forward to him accelerating the commercialization of Bodyport’s solutions to improve heart failure management.”
Bodyport is preparing to commercialize its Bodyport Cardiac Scale, which remotely and noninvasively analyzes heart function and fluid status in people with fluid management conditions.
“I joined Bodyport to help make a difference in patients’ lives. I truly believe our simple, intuitive biomarker platform will be able to do just that,” Lipman told the press. “Bodyport’s growing clinical evidence and commitment to a robust clinical roadmap have the potential to help detect heart failure events accurately and catch them earlier from the comfort of the patient’s home. I look forward to working together with our incredibly talented team and am eager to bring our solutions to market.”
Lipman has over 25 years of leadership experience in the medical device industry. He was most recently president of North America for Qualta Dialysis Technologies. Before that, he was chief commercial officer at NightBalance prior to its acquisition by Philips. He was also previously VP of marketing and sales at ApniCure, and held positions at two Johnson & Johnson subsidiaries, LifeScan and Scios.
“I am delighted to welcome John to the team during this important phase of our growth,” Centen said. “In my new role as president and CTO, I am excited to lead the development of our novel biomarker pipeline and prediction algorithms for managing cardiorenal conditions.”
“John’s extensive industry experience will prove to be a valuable resource to the Bodyport team,” said Phyllis Whiteley, Ph.D., Chair of Bodyport’s board of directors. “We are excited to welcome John as Bodyport’s CEO and look forward to him accelerating the commercialization of Bodyport’s solutions to improve heart failure management.”